Should I buy or sell Immunovant stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMVT shares. View IMVT analyst ratings or view top-rated stocks .

What is Immunovant's stock price target for 2024?

17 analysts have issued 1 year target prices for Immunovant's stock. Their IMVT share price targets range from $32.00 to $57.00. On average, they predict the company's stock price to reach $48.00 in the next twelve months. This suggests a possible upside of 70.1% from the stock's current price. View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts .

How have IMVT shares performed in 2024?

Immunovant's stock was trading at $42.13 at the beginning of 2024. Since then, IMVT stock has decreased by 33.0% and is now trading at $28.22. View the best growth stocks for 2024 here .

When is Immunovant's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our IMVT earnings forecast .

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) posted its quarterly earnings data on Monday, February, 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07.

What ETFs hold Immunovant's stock?

ETFs with the largest weight of Immunovant (NASDAQ:IMVT) stock in their portfolio include SPDR S&P Biotech ETF (XBI) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) , Principal Healthcare Innovators ETF (BTEC) and ProShares Ultra Nasdaq Biotechnology (BIB) . IQ Chaikin U.S. Small Cap ETF (CSML) .

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Walt Disney (DIS) , Fulcrum Therapeutics (FULC) , Myovant Sciences (MYOV) , Alibaba Group (BABA) , Inovio Pharmaceuticals (INO) , JD.com (JD) and Johnson & Johnson (JNJ) .

Who are Immunovant's major shareholders?

Immunovant's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.04%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Atul Pande , Douglas J Hughes , Eva Renee Barnett , Frank Torti , George V Migausky , Julia G Butchko , Mark S Levine , Peter Salzmann , Sciences Ltd Roivant and William L Macias . View institutional ownership trends .

How do I buy shares of Immunovant?

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:IMVT

Immunovant (IMVT) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free IMVT Stock Alerts

$28.22

-0.10 (-0.35%)

(As of 04/19/2024 ET)

Compare

Today's Range: $27.33
▼
$28.64
50-Day Range: $28.32
▼
$38.36
52-Week Range: $15.08
▼
$45.58

Volume: 1.08 million shs
Average Volume: 1.23 million shs
Market Capitalization: $4.10 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $48.00

Get Immunovant alerts:

Immunovant MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 70.1% Upside
$48.00 Price Target
Short Interest: Bearish
14.92% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.21
Based on 7 Articles This Week
Insider Trading: Selling Shares
$595,585 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.70) to ($1.82) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.50 out of 5 stars

Medical Sector

454th out of 911 stocks

Biological Products, Except Diagnostic Industry

65th out of 150 stocks

4.5

Analyst's Opinion

Consensus Rating
Immunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 17 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Immunovant has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
14.92% of the float of Immunovant has been sold short.
Short Interest Ratio / Days to Cover
Immunovant has a short interest ratio ("days to cover") of 7.3.
Change versus previous month
Short interest in Immunovant has recently decreased by 3.53%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Immunovant does not currently pay a dividend.
Dividend Growth
Immunovant does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMVT.

2.3

News and Social Media Coverage

News Sentiment
Immunovant has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Immunovant this week, compared to 4 articles on an average week.
Search Interest
19 people have searched for IMVT on MarketBeat in the last 30 days. This is an increase of 111% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is a decrease of -53% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $595,585.00 in company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Immunovant is held by insiders.
Percentage Held by Institutions
47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Immunovant are expected to decrease in the coming year, from ($1.70) to ($1.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunovant is -15.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunovant is -15.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immunovant has a P/B Ratio of 10.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Immunovant Stock (NASDAQ:IMVT)

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

IMVT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMVT Stock News Headlines

April 11, 2024 | insidertrades.com

Immunovant, Inc. (NASDAQ:IMVT) Insider Julia G. Butchko Sells 1,053 Shares

April 16, 2024 | finance.yahoo.com

Immunovant, Inc. (IMVT) Stock Historical Prices & Data - Yahoo Finance

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 15, 2024 | nasdaq.com

Immunovant is Now Oversold (IMVT)

April 13, 2024 | americanbankingnews.com

Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Rating of "Buy" by Brokerages

April 12, 2024 | investing.com

Immunovant CEO sells over $149,000 in company stock

April 12, 2024 | americanbankingnews.com

Insider Selling: Immunovant, Inc. (NASDAQ:IMVT) Insider Sells 1,053 Shares of Stock

April 12, 2024 | americanbankingnews.com

Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett Sells 3,689 Shares

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 12, 2024 | americanbankingnews.com

Immunovant, Inc. (NASDAQ:IMVT) CEO Peter Salzmann Sells 4,807 Shares

April 12, 2024 | americanbankingnews.com

Equities Analysts Offer Predictions for Immunovant, Inc.'s Q1 2026 Earnings (NASDAQ:IMVT)

April 4, 2024 | seekingalpha.com

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

March 25, 2024 | investorplace.com

Wall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich

March 22, 2024 | markets.businessinsider.com

Buy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab Trials

March 12, 2024 | finanznachrichten.de

Immunovant Inc.: Immunovant Awarded U.S. Patent for IMVT-1402

March 12, 2024 | globenewswire.com

Immunovant Awarded U.S. Patent for IMVT-1402

March 11, 2024 | finance.yahoo.com

IMVT Jul 2024 30.000 call

March 11, 2024 | finance.yahoo.com

IMVT Mar 2024 40.000 call

March 10, 2024 | finance.yahoo.com

IMVT Mar 2024 32.000 call

March 10, 2024 | finance.yahoo.com

IMVT Apr 2024 45.000 put

March 10, 2024 | finance.yahoo.com

IMVT Jan 2025 12.500 put

March 10, 2024 | finance.yahoo.com

IMVT Mar 2024 29.000 put

March 9, 2024 | finance.yahoo.com

IMVT Mar 2024 37.500 put

March 9, 2024 | finance.yahoo.com

IMVT Mar 2024 37.000 call

March 6, 2024 | finance.yahoo.com

IMVT Mar 2024 32.000 put

March 5, 2024 | finance.yahoo.com

IMVT Mar 2024 33.000 put

March 1, 2024 | finance.yahoo.com

IMVT Mar 2024 36.000 call

See More Headlines

Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/12/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/27/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:IMVT
CUSIP: N/A
CIK: 1764013
Web: www.immunovant.com
Phone: 917-580-3099
Fax: N/A
Employees: 164
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $48.00
High Stock Price Target: $57.00
Low Stock Price Target: $32.00
Potential Upside/Downside: +73.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 17 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-210,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -57.97%
Return on Assets: -52.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 22.14
Quick Ratio: 22.14

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.78 per share
Price / Book: 9.93

Miscellaneous

Outstanding Shares: 145,290,000
Free Float: 138,319,000
Market Cap: $4.01 billion
Optionable: Optionable
Beta: 0.65

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Frank M. Torti M.B.A. (Age 45)
M.D., Executive Chairperson of the Board
Comp: $92.5k
Dr. Peter Salzmann M.B.A. (Age 55)
M.D., CEO & Director
Comp: $1.02M
Ms. Eva Renee Barnett M.B.A. (Age 44)
Chief Financial Officer
Comp: $871.07k
Dr. William L. Macias M.D. (Age 66)
Ph.D., Chief Medical Officer
Comp: $719.88k
Dr. Jay S. Stout Ph.D. (Age 61)
Chief Technology Officer
Dr. Chau Cheng M.B.A.
Ph.D., Vice President of Investor Relations
Mr. Mark S. Levine (Age 51)
Chief Legal Officer & Corporate Secretary
Ms. Lauren Schrier M.B.A.
Vice President of Marketing
Ms. Christine Blodgett
Vice President of Human Resources
Dr. Julia G. Butchko Ph.D. (Age 53)
Chief Development Officer
Comp: $531k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IMVT Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunovant stock right now?: 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMVT shares.
View IMVT analyst ratings or view top-rated stocks.
What is Immunovant's stock price target for 2024?: 17 analysts have issued 1 year target prices for Immunovant's stock. Their IMVT share price targets range from $32.00 to $57.00. On average, they predict the company's stock price to reach $48.00 in the next twelve months. This suggests a possible upside of 70.1% from the stock's current price.
View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts.
How have IMVT shares performed in 2024?: Immunovant's stock was trading at $42.13 at the beginning of 2024. Since then, IMVT stock has decreased by 33.0% and is now trading at $28.22.
View the best growth stocks for 2024 here.
When is Immunovant's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our IMVT earnings forecast.
How were Immunovant's earnings last quarter?: Immunovant, Inc. (NASDAQ:IMVT) posted its quarterly earnings data on Monday, February, 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07.

What ETFs hold Immunovant's stock?: ETFs with the largest weight of Immunovant (NASDAQ:IMVT) stock in their portfolio include SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and ProShares Ultra Nasdaq Biotechnology (BIB).IQ Chaikin U.S. Small Cap ETF (CSML).
What other stocks do shareholders of Immunovant own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).
Who are Immunovant's major shareholders?: Immunovant's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.04%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias.
View institutional ownership trends.
How do I buy shares of Immunovant?: Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMVT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Immunovant (IMVT) Stock Price, News & Analysis

Immunovant MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Immunovant Stock (NASDAQ:IMVT)

IMVT Stock Price History

IMVT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IMVT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™